120-OR: Efficacy of Tirzepatide in Achieving the Composite Endpoints of Glycemic, Blood Pressure, and Lipid Goals in SURMOUNT-2
Authors: SATTAR NAVEED , CHENG ALICE Y.Y. , BENABBAD IMANE , LEE CLARE , KYOUNGAH SEE SOPHIA , LEECH JOHN , MOJDAMI DONNA 
Published: June 2024

In the SURMOUNT-2 (SM-2) trial of adults with overweight/obesity and type 2 diabetes (T2D), tirzepatide (TZP), a once weekly GIP/GLP-1 receptor agonist, significantly reduced body weight (BW) in conjunction with a reduced calorie diet and increased physical activity. This post-hoc analysis assessed the proportion of participants achieving composite endpoints of BP &lt;130/80 mm Hg, non-HDL &lt;130 mg/dl, and three HbA1c thresholds of &lt;7%, &lt; 6.5% and &lt;5.7% at 72 weeks. Logistic regression with missing value imputed by mixed model repeated measures, using the efficacy estimand, assessed participants who achieved the composite endpoints, in the 10mg (N=312) or 15mg (N=311) TZP groups, versus placebo (PBO) (N=315). Overall baseline mean BW was 100.7 kg, BMI 36.1kg/m2, HbA1c 8.02%, BP 130.5/79.8 mm Hg and non-HDL 132.5 mg/dl. For 15mg TZP, 33.8%, 32.8%, and 25.9% of participants achieved the composite endpoints versus 7.5%, 3.9%, and 0.7% of PBO at 72 weeks (Fig). Findings for the TZP 10mg group were similar to those observed in the 15mg group. In people with T2D and overweight/obesity, higher proportion of participants receiving TZP achieved clinically meaningful composite endpoints, which included BP, lipids and HbA1c goals compared to PBO. This suggests that TZP can help achieve multiple clinical goals, in addition to meaningful weight loss, important for improving cardiometabolic health.

Disclosure

N. Sattar: Other Relationship; Abbott, Amgen Inc., AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Company, AbbVie Inc. Consultant; Menarini-Ricerche. Other Relationship; Novartis AG, Novo Nordisk, Pfizer Inc., Roche Diagnostics, American Diabetes Association, Medscape. A.Y.Y. Cheng: Advisory Panel; Abbott. Speaker's Bureau; Amgen Inc., AstraZeneca, Bausch Health. Advisory Panel; Bayer Inc. Speaker's Bureau; Abbott, Bayer Inc. Research Support; Applied Therapeutics Inc. Advisory Panel; Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim, Dexcom, Inc. Advisory Panel; Dexcom, Inc., Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Eisai Inc. Speaker's Bureau; GlaxoSmithKline plc. Advisory Panel; HLS Therapeutics Inc. Speaker's Bureau; HLS Therapeutics Inc., Insulet Corporation. Advisory Panel; Insulet Corporation, Janssen Pharmaceuticals, Inc. Speaker's Bureau; Janssen Pharmaceuticals, Inc., Medtronic. Advisory Panel; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Research Support; Novo Nordisk. Speaker's Bureau; Pfizer Inc. Advisory Panel; Sanofi. Speaker's Bureau; Sanofi. Research Support; Sanofi. Advisory Panel; Takeda Canada, AstraZeneca, Sanofi. Consultant; Abbott, AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Dexcom, Inc., Eisai Inc., Eli Lilly and Company, Insulet Corporation, HLS Therapeutics Inc., Janssen Pharmaceuticals, Inc., Novo Nordisk, Sanofi, Takeda Pharmaceutical Company Limited. I. Benabbad: Employee; Eli Lilly and Company. C. Lee: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. S. See: Employee; Eli Lilly and Company. J. Leech: Employee; Eli Lilly and Company. D. Mojdami: Employee; Eli Lilly and Company.